Next Article in Journal
Fungal Endophytic Community Associated with Guarana (Paullinia cupana Var. Sorbilis): Diversity Driver by Genotypes in the Centre of Origin
Next Article in Special Issue
Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
Previous Article in Journal
Chromatin Structure and Drug Resistance in Candida spp.
Previous Article in Special Issue
Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
Open AccessReview

Review of the Novel Investigational Antifungal Olorofim

Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
J. Fungi 2020, 6(3), 122; https://doi.org/10.3390/jof6030122
Received: 5 July 2020 / Revised: 27 July 2020 / Accepted: 29 July 2020 / Published: 30 July 2020
(This article belongs to the Special Issue Antifungal Agents Recently Approved or Under Development)
The incidence of invasive fungal infections caused by molds and endemic fungi is increasing. There is also concern regarding increased rates of reduced susceptibility or frank resistance among Aspergillus and Coccidioides species, while Scedosporium species, Lomentospora prolificans, and Fusarium species are inherently less susceptible or intrinsically resistant to clinically available antifungals. Olorofim (formerly F901318) is the first member of the orotomide class of antifungals to be evaluated clinically for the treatment of invasive mold infections. This agent inhibits dihydroorotate dehydrogenase, a key enzyme in the biosynthesis of pyrimidines. Olorofim has activity against many molds and thermally dimorphic fungi, including species that are resistant to azoles and amphotericin B, but lacks activity against yeasts and the Mucorales. It is currently being developed for both oral and intravenous administration. Although published clinical outcome data have been limited to case reports to date, the results against invasive and refractory infections are promising. This review describes the mechanism of action of olorofim, its in vitro spectrum of activity, and what is currently known about its pharmacokinetic profile and clinical efficacy. View Full-Text
Keywords: Olorofim; F901318; invasive mold infections; dihydroorotate dehydrogenase; Aspergillus; Scedosporium; in vitro susceptibility Olorofim; F901318; invasive mold infections; dihydroorotate dehydrogenase; Aspergillus; Scedosporium; in vitro susceptibility
Show Figures

Figure 1

MDPI and ACS Style

Wiederhold, N.P. Review of the Novel Investigational Antifungal Olorofim. J. Fungi 2020, 6, 122.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop